129 related articles for article (PubMed ID: 16882082)
41. Extent of prostatic atrophy in needle biopsies and serum PSA levels: is there an association?
Billis A; Meirelles LR; Magna LA; Baracat J; Prando A; Ferreira U
Urology; 2007 May; 69(5):927-30. PubMed ID: 17482936
[TBL] [Abstract][Full Text] [Related]
42. [A case of prostate cancer with cyst formation].
Kim SC; Fujimoto K; Matsumoto Y; Cho M; Natsume O; Uemura H; Ozono S; Hirao Y
Hinyokika Kiyo; 2001 Sep; 47(9):653-6. PubMed ID: 11692605
[TBL] [Abstract][Full Text] [Related]
43. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
44. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?
Uchida T; Illing RO; Cathcart PJ; Emberton M
BJU Int; 2006 Sep; 98(3):537-9. PubMed ID: 16925749
[TBL] [Abstract][Full Text] [Related]
45. A decrease in 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma.
Averna TA; Kline EE; Smith AY; Sillerud LO
J Urol; 2005 Feb; 173(2):433-8. PubMed ID: 15643195
[TBL] [Abstract][Full Text] [Related]
46. Prostate-specific antigen-positive extramammary Paget's disease--association with prostate cancer.
Hammer A; Hager H; Steiniche T
APMIS; 2008 Jan; 116(1):81-8. PubMed ID: 18254784
[TBL] [Abstract][Full Text] [Related]
47. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
[TBL] [Abstract][Full Text] [Related]
48. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
Choueiri TK; Dreicer R; Paciorek A; Carroll PR; Konety B
J Urol; 2008 Mar; 179(3):906-10; discussion 910. PubMed ID: 18207194
[TBL] [Abstract][Full Text] [Related]
49. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
[TBL] [Abstract][Full Text] [Related]
50. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
[TBL] [Abstract][Full Text] [Related]
51. Outcome for repeated biopsy of the prostate: roles of serum PSA, small atypical glands, and prostatic intraepithelial neoplasia.
Brimo F; Vollmer RT; Corcos J; Humphrey PA; Bismar TA
Am J Clin Pathol; 2007 Oct; 128(4):648-51. PubMed ID: 17875517
[TBL] [Abstract][Full Text] [Related]
52. The influence of statin medications on prostate-specific antigen levels.
Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ
J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682
[TBL] [Abstract][Full Text] [Related]
53. Metastatic prostate cancer masquerading clinically and radiologically as a primary caecal carcinoma.
Kabeer MA; Lloyd-Davies E; Maskell G; Hohle R; Mathew J
World J Surg Oncol; 2007 Jan; 5():2. PubMed ID: 17207288
[TBL] [Abstract][Full Text] [Related]
54. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
Shao Q; Song J; Zhou ZJ; Du LD
Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
[TBL] [Abstract][Full Text] [Related]
55. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
56. Is there a role for serum human tissue kallikrein in detection of prostate cancer?
Ochiai A; Shukla A; Davis JW; Fritsche HA; Bhadkamkar V; Babaian RJ
Urology; 2007 Sep; 70(3):519-22. PubMed ID: 17905108
[TBL] [Abstract][Full Text] [Related]
57. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels.
Dai B; Ye DW; Kong YY; Shen YJ; Wang BH
Asian J Androl; 2008 Mar; 10(2):325-31. PubMed ID: 18097514
[TBL] [Abstract][Full Text] [Related]
58. [Estramustine phosphate withdrawal syndrome in relapsed prostate cancer: two case reports].
Kobayashi S; Tsukamoto T; Tohsaka A; Tohma T
Hinyokika Kiyo; 2008 Jun; 54(6):423-6. PubMed ID: 18634439
[TBL] [Abstract][Full Text] [Related]
59. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815
[TBL] [Abstract][Full Text] [Related]
60. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE
Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
